Avenzoar Pharmaceuticals
Avenzoar Pharmaceuticals is a research-focused biotechnology company dedicated to the discovery and development of innovative cancer therapies.
Our cancer drugs are aimed at targeting and inhibiting mechanisms of metastasis
and drug resistance. These cancer drugs are aimed at targeting and inhibiting mechanisms of metastasis and drug resistance.
Founded on the principles of scientific excellence and patient-centric care, we strive to make a meaningful impact on the lives of cancer patients worldwide.
KEY ACCOMPLISHMENTS
2016
Entered exclusive worldwide license agreement with Cedars-Sinai covering two compounds (AP-001 & AP-002) and received U.S. FDA Orphan Drug Designation for Pancreatic Cancer.
2016-2024
Granted U.S. patents for treating cancer & metastasis. Granted patents in various other countries.
2019
Awarded Small Business Innovation Research (SBIR) grant by National Institutes of Health.
2023
Secured $2.9 million in convertible note financing from Ally Capital.
2025
Submitted additional global patent filings around AP-001 with Pancreatic Cancer Organoids (AP-001 patent path to 2045).
2026
AP-001 Pre-IND questions and briefing book prepared for the U.S. FDA
Our strategy
To become a leader in oncology research and development by bringing novel, effective, and safe treatments to cancer patients worldwide. We focus on identifying therapeutics that target key cancer-promoting pathways, particularly by aiming at tumor microenvironment and metastasis. Our pipeline includes the small-molecule drugs AP-001 and AP-002, which are IV-based and oral therapeutics targeting cancer-promoting pathways, tumor microenvironment, and drug resistance.
Opportunities
We are seeking opportunities to collaborate and bring our innovative therapies to market. Avenzoar’s deep expertise in cancer research and drug development.
At our core, we embody innovation by pushing the boundaries of science to develop cutting-edge therapies uphold integrity by conducting research with the highest ethical standards, foster collaboration by partnering with industry leaders to advance cancer treatment, and maintain a steadfast Patient Focus by keeping cancer patients at the heart of everything we do.
Shirley Widjaja
Board of Directors
Shirley Widjaja
Shierley Widjaja has served on Avenzoar’s Board of Directors since 2023. She has an impressive background in the biotech and pharmaceutical industries, and serves as a Director at Prometheus Laboratories, Inc., and previously served as a Director at Prometheus Biosciences, Inc. Shierley worked as a Qualitative Research Associate at McKinley Capital Management. She holds an undergraduate degree from the University of California, Los Angeles, and an MBA from The Wharton School at the University of Pennsylvania.
